Director Dealing
25 June 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, confirms that as announced on 20 May 2025, Mr Cathal Friel, Executive Chair and PDMR of the Company, participated in the Fundraising subscribing for 4,000,000 new Ordinary Shares at a price of 2.5p per share (the Issue Price). Following the AGM earlier this week, the New Ordinary Shares issued pursuant to the Fundraising were admitted to trading at 8am today.
Following this transaction, Cathal Friel holds a total of 41,219,757 ordinary shares in the Company, representing approximately 5.91% of the Company’s issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a. |
Name of PDMR |
Cathal Friel |
|
|
2 |
Reason for notification
|
||
|
a. |
Position/Status |
Executive Chair |
|
|
b. |
Initial notification/ Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a. |
Name |
Poolbeg Pharma plc |
|
|
b. |
LEI |
213800UZ8WJLWYHBFL52 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a. |
Description of the financial instrument, type of instrument
|
Ordinary shares of 0.02 pence each
ISIN GB00BKPG7Z60 |
|
|
b. |
Nature of the transaction |
Purchase of ordinary shares in connection with the fundraising initially announced on 20 May 2025. |
|
|
c. |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
2.5p |
4,000,000 |
||
|
d. |
Aggregated information
– Aggregated Volume
– Price |
As in 4c) above
|
|
|
e. |
Date of the transaction |
25 June 2025 |
|
|
f. |
Place of the transaction |
London Stock Exchange, AIM Market (XLON)
|
|
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO |
+44 (0) 207 183 1499 |
